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Introduction: Small-cell lung cancer (SCLC) accounts for 15% 
of all lung cancers and has been understudied for novel therapies. 
Signaling through fibroblast growth factors (FGF2, FGF9) and their 
high-affinity receptor has recently emerged as a contributing factor 
in the pathogenesis and progression of non–small-cell lung cancer. In 
this study, we evaluated fibroblast growth factor receptor 1 (FGFR1) 
and ligand expression in primary SCLC samples.
Methods: FGFR1 protein expression, messenger RNA (mRNA) 
levels, and gene copy number were determined by immunohis-
tochemistry (IHC), mRNA in situ hybridization, and silver in situ 
hybridization, respectively, in primary tumors from 90 patients with 
SCLC. Protein and mRNA expression of the FGF2 and FGF9 ligands 
were determined by IHC and mRNA in situ hybridization, respec-
tively. In addition, a second cohort of 24 SCLC biopsy samples with 
known FGFR1 amplification by fluorescence in situ hybridization 
was assessed for FGFR1 protein expression by IHC. Spearman cor-
relation analysis was performed to evaluate associations of FGFR1, 
FGF2 and FGF9 protein levels, respective mRNA levels, and FGFR1 
gene copy number.
Results: FGFR1 protein expression by IHC demonstrated a signifi-
cant correlation with FGFR1 mRNA levels (p < 0.0001) and FGFR1 
gene copy number (p = 0.03). The prevalence of FGFR1 mRNA posi-
tivity was 19.7%. FGFR1 mRNA expression correlated with both 
FGF2 (p = 0.0001) and FGF9 (p = 0.002) mRNA levels, as well as 
with FGF2 (p = 0.01) and FGF9 (p = 0.001) protein levels. There was 
no significant association between FGFR1 and ligands with clinical 
characteristics or prognosis. In the second cohort of specimens with 
known FGFR1 amplification by fluorescence in situ hybridization, 
23 of 24 had adequate tumor by IHC, and 73.9% (17 of 23) were 
positive for FGFR1 protein expression.
Conclusions: A subset of SCLCs is characterized by potentially 
activated FGF/FGFR1 pathways, as evidenced by positive FGF2, 
FGF9, and FGFR1 protein and/or mRNA expression. FGFR1 pro-
tein expression is correlated with FGFR1 mRNA levels and FGFR1 
gene copy number. Combined analysis of FGFR1 and ligand 
expression may allow selection of patients with SCLC to FGFR1 
inhibitor therapy.
Key Words: Small-cell lung cancer, Fibroblast growth factor recep-
tor 1, Fibroblast growth factor 2, Fibroblast growth factor 9.
(J Thorac Oncol. 2015;10: 1083–1090)
Small-cell lung cancer (SCLC) comprises approximately 15% of all lung cancers with more than 30,000 new cases 
per year in the United States.1 SCLC is an extremely aggres-
sive malignancy, with less than 5% survival 3 years after diag-
nosis. No major therapeutic progress has been achieved in 
SCLC in the past decades. Identification of new therapies in 
SCLC is urgently needed.
Novel molecularly targeted therapies, such as epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors and 
anaplastic lymphoma kinase (ALK) inhibitors, have dramati-
cally improved the clinical course for advanced non–small-
cell lung cancer (NSCLC) patients with EGFR mutations 
and ALK rearrangements, respectively.2,3 However, there are 
no approved molecularly targeted therapies for patients with 
SCLC. Part of the reason for the lack of improvement in care 
of patients with SCLC is that there is limited availability of 
tissue for molecular studies due to difficulties in obtaining suf-
ficient tumor samples. This highlights the value of performing 
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and reporting research on available SCLC tissue to advance 
the identification of novel therapeutically relevant genomic 
alterations in this disease.
This study focuses on defining the fibroblast growth fac-
tor (FGF)/fibroblast growth factor receptor (FGFR) signaling 
pathway as a target for drug therapy in patients with SCLC. 
FGFs comprise a complex family of signaling molecules that 
have been implicated in angiogenesis and inflammation in a 
wide variety of human disorders.4 Activation of the FGFR1 
signaling pathway is thought to drive epithelial-to-mesen-
chymal transition, transforming normal cells to tumor cells. 
Twenty-three FGFs and four FGFRs (FGFR1–FGFR4) have 
been identified. Results of several studies have demonstrated 
the coexpression of FGF2 and FGF9 ligands in association 
with FGFR1 in human lung cancers.5,6 The binding of FGF 
ligands to FGFRs mediates signal transduction through induc-
tion of receptor dimerization and promotes a cascade of down-
stream Ras-dependent mitogen-activated protein kinase and 
Ras-independent phosphoinositide 3-kinase–Akt signaling 
pathways. Other pathways can also be activated by FGFRs, 
including signal transducer and activator of transcription 
(STAT)-dependent signaling.7 The FGF/FGFR signaling path-
way has been implicated as an autocrine signaling loop that 
leads to tumor proliferation and angiogenesis in a variety of 
NSCLC cell lines.6
The FGFR1 gene is located on the short arm of chromo-
some 8 (8p12) and is a member of the FGFR family of tyrosine 
kinase receptors. FGFR1 amplification, translocation, and 
point mutations have been described in several tumor types, 
including breast, prostate, esophageal, bladder, and endome-
trial cancers and recently in 13% to 25% of squamous-cell 
lung cancers (SqCCs).7–10 In addition, FGFR1 amplification/
overexpression has also been found in a subset of patients 
with non-SqCC NSCLC.11 Recent genomic analysis of a set 
of 29 SCLC samples has revealed focal FGFR1 amplification 
among other molecular aberrations.12
FGF2 is a mitogen and a survival factor in many exper-
imental models and is involved in neoangiogenesis in vivo. 
Evidence suggests that FGF2 induces proliferation and che-
moresistance in SCLC cells.13 High levels of serum FGF2 
have been associated with poor prognosis in SCLC, possibly 
because of an FGF2-mediated cytoprotective effect, whereby 
the expression of antiapoptotic proteins is upregulated, pro-
moting resistance to current anticancer treatment.14 However, 
studies of the FGF2 and FGF9–FGFR1 signaling pathway 
have been typically performed on small series of SCLC tumor 
samples, likely due to limited availability of SCLC specimens.
Preclinical evidence suggests that SCLC patients may 
benefit from FGFR inhibitor therapy. Different FGFR inhibi-
tors such as BGJ 398 (Novartis, Switzerland), AZD 4547 
(AstraZeneca, UK), Ponatinib (Ariad, Cambridge, MA), and 
LY2874455 (Eli Lilly, Indianapolis, IN) are currently in phase 
I and II clinical trials.7 The FGFR inhibitor PD173074 has 
blocked SCLC growth both in vitro and in vivo.13 A small 
interfering RNA against FGF2 and FGF-ligand traps (FP-
1039) have been developed to inhibit FGF ligands in vitro.15,16 
Thus, FGFR and its ligands are promising therapeutic targets.
The aim of this study was to describe the characteris-
tics of the FGF–FGFR1 signaling pathway in SCLC. We first 
assessed the frequency of FGFR1, FGF2, and FGF9 protein 
and messenger RNA (mRNA) expression and FGFR1 gene 
amplification from a series of 90 surgically resected primary 
SCLCs. Next, we assessed the frequency of FGFR1 protein 
expression in second cohort of 24 SCLC biopsy samples 
with known FGFR1 amplification. Our goal with the second 
cohort was to confirm the ability of our selected FGFR1 anti-
body and methods to detect FGFR1 amplification and to bet-
ter understand the correlation between FGFR1 amplification 
and protein expression. We analyzed the data to investigate 
associations among levels of FGFR1, FGF2, and FGF9 pro-
tein and respective mRNA levels, FGFR1 gene amplification, 
and clinical characteristics. To our knowledge, this is the first 
study to provide a comprehensive analysis of the FGF2 and 
FGF9–FGFR1 signaling pathway in SCLC.
MATERIALS AND METHODS
Patient Population and Tumor Specimens
Two cohorts of SCLC specimens were studied sequen-
tially. The first cohort was primary SCLC tumor specimens 
collected from a series of patients with limited disease who 
underwent pulmonary resection.17 Archival formalin-fixed 
paraffin-embedded tumor samples were obtained from a unique 
series of 90 patients with SCLC who underwent pulmonary 
resection between 1982 and 2002 at the Medical University 
of Gdansk, Poland. In most patients, SCLC histology was 
established at the time of surgery. All primary diagnoses were 
reviewed by three experienced pathologists according to the 
2004 World Health Organization criteria.18 For all patients, 
medical records were reviewed to obtain clinical characteristics, 
including age, gender, tumor diameter, tumor, node, metastasis 
stage, and overall survival. In all patients, surgery was followed 
by standard chemotherapy. Median follow-up was 17.8 months 
(range, 1–212 mo), median survival was 18.7 months, and the 
probability of survival 2 years after diagnosis was 42%.
The second cohort of 24 SCLC biopsy cases was from 
the Institute of Pathology at the University Hospital Cologne, 
Germany, with known FGFR1 amplification by fluorescence 
in situ hybridization (FISH).19 All of these cases met our cri-
teria for FGFR1 amplification (FGFR1 gene signals ≥ 6 per 
nucleus or FGFR1/CEN8 ratio ≥ 2).
Tissue Microarray Construction
Ninety surgically resected SCLC specimens from 
the first cohort were constructed into a tissue microarray 
(TMA) using a manual MTA-1 Beecher Instrument (Beecher 
Instruments, Inc, Sun Prairie, WI). Briefly, morphologically 
representative areas of SCLC were identified and annotated on 
a hematoxylin and eosin–stained slide under the microscope 
by a pathologist. The annotated slides were used to guide dis-
section of three 0.6-mm diameter cores from different tumor 
areas of the paraffin-embedded blocks. The triplicate cores 
were set into TMA blocks.
Immunohistochemistry
Immunohistochemistry (IHC) on 4-μm sections was 
performed using primary commercially available antibodies 
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(FGFR1, Clone EPR806Y, 1:50, catalog [Cat]. TA301021; 
Origene, Rockville, MD; FGF2, Clone N-19, 1:50, Cat. 
Sc-1390-R; Santa Cruz, Dallas, TX; FGF9, Clone D-8, 
1:250, Cat. Sc-8413; Santa Cruz) following manufacturer 
instructions. The specimens were processed on the Ventana 
BenchMark XT autostainer utilizing the ultraView detection 
kit (Ventana, Tucson, AZ).
Scoring for protein expression was determined accord-
ing to the hybrid scoring system (H-score) criteria. Specimens 
were scored based on whichever cellular compartment pre-
dominantly stained. For FGFR1, the predominantly stained 
and scored compartment was always cytoplasmic and/or mem-
branous. For FGF2 and FGF9, specimens demonstrated cyto-
plasmic and/or nuclear staining. Scoring was performed with 
the H-score based on the percentage of tumor cells staining 
at various intensities as follows: 0 × (% tumor cells with no 
staining) + 1 × (% with faint expression) + 2 × (% with mod-
erate expression) + 3 × (% with strong expression). H-scores 
for specimens with multiple cores were averaged. Specimens 
were deemed adequate if at least one core was scored. Three 
pathologists (LZ, TAB, and HY) independently scored the first 
(n = 90) and the second cohort (n = 24). For discrepant results, 
a final score was determined by a consensus conference of the 
pathologists.
mRNA In Situ Hybridization
mRNA in situ hybridization (ISH) was performed on 
the tumor tissue using the RNA scope 2.0 assay system with 
recommended probes from Advanced Cell Diagnostics, Inc. 
(Hayward, CA) (FGFR1 Cat. 310071, FGF2 Cat. 312111, and 
FGF9 Cat. 300031). ISH scores were generated and recorded 
using the following algorithm at 200 × magnification: 0, no 
staining; 1, 1 to 3 dots per tumor cell; 2, 4 to 10 dots per tumor 
cell; 3, more than 10 dots per cell with less than 10% tumor 
cells with dot clusters; 4, more than 10 dots per cell or more 
than 10% tumor cells with dot clusters as per the RNA scope 
system scoring guidelines.20
FGFR1 Gene Copy Number Analysis 
by Silver In Situ Hybridization 
Dual-color silver in situ hybridization (SISH) was per-
formed on 4-μm sections of the TMA, using a fully automated 
protocol on the Ventana BenchMark XT instrument (Ventana). 
All reagents, including FGFR1 2,4-Dinitrophenol (DNP) 
probe (FGFR1 locus on 8p12, Cat. 760–1217) and chromo-
some 8 digoxigenin (DIG) probe (Centromere 8 [CEN8] Cat. 
760–1220) cocktails, ultraView SISH, and ultraView Alkaline 
Phosphatase Red ISH detection kits, were obtained from 
Ventana Medical Systems Inc. (Tucson, AZ).
FGFR1 and CEN8 signals were counted separately 
in 50 nonoverlapping tumor nuclei per core. FGFR1 minor 
signal clusters and major signal clusters were counted as 
6 and 12 signals, respectively (according to the Ventana 
Interpretation Guide by Grogan et al.; see supplementary 
material, Supplementary Digital Content, http://links.lww.
com/JTO/A837).
For each core, the mean copy number per nucleus of 
each probe (FGFR1 and CEN8), the FGFR1/CEN8 ratio, 
and the percentage of cells with FGFR1 signal clusters were 
calculated. FGFR1 amplification was defined as an average 
of at least four FGFR1 signals per nucleus or FGFR1/CEN8 
ratio at least 2. These criteria are in accordance with the 
American Society of Clinical Oncology/College of American 
Pathologists updated 2013 guidelines for assessment of HER2 
amplification status in breast cancer and have been used in 
prior FGFR1 studies.11,21,22 Two pathologists (LZ and TAB) 
independently scored each core. Any specimens with discrep-
ant results were re-evaluated by both pathologists for a con-
sensus final result.
FGFR1 Evaluation by FISH
FISH was performed on two cases with positive pro-
tein expression but negative FGFR1 SISH amplification 
results. Slides were subjected to a three-color FISH assay 
using a FGFR1 break-apart/amplification probe set consist-
ing of three reagents: a green telomeric probe for FGFR1, a 
red centromeric probe for FGFR1, and an aqua centromeric 
probe for the centromere of chromosome 8 (CEN8; Cytocell, 
Cambridge, United Kingdom, Cat. LPS 018 - SA). Fifty 
nuclei per specimen were analyzed for FGFR1 amplification 
or rearrangement (described more in detail in supplementary 
material, Supplementary Digital Content, http://links.lww.
com/JTO/A837). FGFR1 amplification was defined as aver-
age FGFR1 copies of at least six fused red/green signals per 
nucleus or a FGFR1/CEN8 ratio at least 2.
Statistical Analysis
Statistical analyses were performed with SAS (version 
9.4; SAS Institute Inc., Cary, NC). The Student’s t test was 
used to evaluate associations between continuous variables, 
including protein expression (H-score 0–300), mRNA expres-
sion (score 0–4), gene amplification (copy number), and 
patient characteristics (age and tumor diameter). The Fisher’s 
exact test was used to evaluate associations between categori-
cal variables, including protein expression, mRNA expres-
sion and FGFR1 amplification (positive versus negative), and 
patient characteristics (sex and stage of disease). Spearman 
correlation was used to analyze the correlation between 
FGFR1, FGF2, FGF9 protein and mRNA expression levels 
and FGFR1 amplification. Kaplan–Meier survival curves 
were plotted based on overall survival time defined as time 
from surgery to last follow-up date or date of death. The asso-
ciation between overall survival time with protein expression, 
mRNA expression, and FGFR1 amplification were analyzed 
using the log-rank test. All tests were considered statistically 
significant with p-value of less than 0.05.
RESULTS
Prevalence and Correlation of FGFR1, 
FGF2, and FGF9 Protein Expression
Of 90 specimens from the first cohort of SCLC cases 
from Poland, FGFR1, FGF2, and FGF9 protein expression 
was evaluable in 83, 75, and 76 specimens, respectively. Of 
the specimens that could not be evaluated, we either lacked 
adequate tissue for all biomarkers or deemed the slide for a 
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tested biomarker inadequate due to too few viable tumor cells. 
Most of the specimens showed homogeneous staining with 
little variability of staining of tumor cells in each specimen 
for FGFR1, FGF2, and FGF9 protein (Supplementary Table 
1, Supplementary Digital Content, http://links.lww.com/JTO/
A837). FGFR1 protein expression tended to be observed in 
the cytoplasm and/or membrane, whereas for FGF2 and FGF9, 
staining was more often localized to the nucleus and/or cyto-
plasm (Fig. 1). These observations are consistent with prior 
studies demonstrating that FGF ligands translocate to the cell 
nucleus.5,23 Scoring was performed on whichever cellular com-
partment showed the highest protein expression. The average 
H-score per specimen was calculated based on all evaluable 
cores. An H-score more than 10 was defined as the cutoff for 
FGFR1, FGF2, and FGF9 protein expression positivity due 
to the inherent difficulty in distinguishing between protein 
expression and artifact in specimens with H-scores of 10 and 
under. However, there is no standardized definition for positiv-
ity for the FGFR1, FGF2, or FGF9 proteins by the H-score sys-
tem with no known biologically relevant cutoff for positivity.
Of the evaluated specimens, 7.2% of the specimens (6 of 
83) were positive for FGFR1 protein expression. The H-scores 
of FGFR1 protein were zero in 75 cases (90.4%), between 0 
and 10 for two cases, and greater than 10 in six cases (7.2%). 
The mean H-score was 9.4, and the range of H-scores was 0 
to 285. There was a clear separation between the H-score of 5 
for the highest negative case and the H-score of 40 for the low-
est positive case (Supplementary Table 1 and Supplementary 
Figure 1, Supplementary Digital Content, http://links.lww.
com/JTO/A837). FGF2 protein expression was positive in 
82.7% of the specimens (62 of 75), and 63.2% of the speci-
mens (48 of 76) were positive for FGF9 protein expression. 
Significant positive correlations were observed between 
FGFR1 and FGF9 (p = 0.01, n = 71) and FGF2 and FGF9 
protein expression levels (p < 0.0001, n = 74; Table 1). The 
analysis for correlation between FGFR1 and FGF2 expression 
levels did not achieve statistical significance (p = 0.1, n = 71).
No significant association was observed between FGFR1, 
FGF2, or FGF9 protein expression and clinical characteristics 
(age, gender, or tumor diameter). A significant association 
between FGFR1 protein expression and stage was observed 
with the Fisher’s exact test (p = 0.012) but does not follow a 
logical order by stage with 3.6% positivity for stage I (n = 28), 
25.0% for stage II (n = 16), and 2.7% for stages III and IV 
(n = 38). The significant p-value may be the result of a chance 
finding due to a small overall number of positive samples 
(n = 6). FGFR1, FGF2, and FGF9 protein expressions were not 
associated with prognosis (all log-rank p-values > 0.05).
Prevalence and Correlation of FGFR1, 
FGF2, and FGF9 mRNA Levels
Evaluation of 76 SCLC specimens by FGFR1 mRNA 
ISH revealed 19.7% (15 of 76) with a positive score defined 
as at least 3; 9.2% (7 of 76) had a score of 4. As there is no 
standard definition for positivity of mRNA ISH, we defined 
FIGURE 1. A–C, FGFR1, FGF2, and FGF9 protein expression in small-cell lung cancer (immunohistochemistry, 200× original 
magnification). A, Positive for cytoplasmic and membranous FGFR1 protein expression (H-score = 285). B, Positive for nuclear 
and cytoplasmic FGF2 protein expression (H-score = 160). C, Positive for nuclear and cytoplasmic FGF9 protein expression 
(H-score = 100); a–c, Negative for FGFR1, FGF2, and FGF9 protein expression (H-score = 0). FGF, fibroblast growth factor; FGFR, 
fibroblast growth factor receptor; H-score, hybrid scoring system.
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at least 3 as the cutoff for mRNA ISH positivity based on the 
presence of mRNA signal dot clusters in cases with a score 
of 3 or higher. All the specimens were negative for FGF2 
and FGF9 mRNA expression with RNA expression scores 
of less than 3. Even so, FGFR1 mRNA expression corre-
lated with both FGF2 mRNA levels (p = 0.0001) and FGF9 
mRNA levels (p = 0.002) (Fig. 2). There was also a signifi-
cant correlation between FGF2 and FGF9 mRNA expression 
levels (p = 0.0004). No significant association was observed 
between FGFR1, FGF2, and FGF9 mRNA expression and 
clinical characteristics or prognosis.
Prevalence of FGFR1 Amplification by SISH
FGFR1 gene copy number was evaluable by SISH in 77 
SCLCs. FGFR1 amplification, defined as at least 4 FGFR1 
signals per nucleus or FGFR1/CEN8 ratio at least 2.0, was 
identified in 6 of 77 cases (7.8%). A representative image 
of a case with positive FGFR1 amplification is depicted in 
Figure 3. All amplified cases (n = 6) were positive for both high 
FGFR1 gene copy number and high FGFR1/CEN8 ratio. In 
the amplified cases, mean FGFR1 signal per nucleus was 6.2 
(range, 4.4–8.9) and mean FGFR1/CEN8 ratio was 4.5 (range, 
2.2–8.0). The amplified tumors had gene signal clusters in 30% 
to 90% of the tumor cells. Tumor FGFR1 amplification was 
caused by increased gene copy number gain on the chromo-
some and not chromosome polysomy, as none of the positive 
specimens had more than three CEN8 signals per nucleus. No 
associations were detected between FGFR1 amplification and 
age, gender, tumor diameter, stage, or overall survival.
FGFR1 Gene Analysis by FISH
FISH was performed on two cases, which were positive 
for FGFR1 protein expression by IHC but negative for FGFR1 
gene amplification by SISH. One specimen had an average of 
TABLE 1.  Spearman’s Correlation Matrix of the FGFR1, FGF2, and FGF9 in Small-Cell Lung Cancer Specimens
FGFR1 IHC FGF-2 IHC FGF-9 IHC FGFR1 mRNA FGF-2 mRNA FGF-9 mRNA
FGF-2 IHC r2, 0.19
p, 0.11
n, 71
FGF-9 IHC 0.29 0.57
0.01 <0.0001
71 74
FGFR1 mRNA 0.51 0.30 0.37
<0.0001 0.01 0.0012
73 73 73
FGF-2 mRNA 0.28 0.31 0.42 0.42
0.02 0.01 0.0002 0.0001
75 74 74 76
FGF-9 mRNA 0.14 0.26 0.21 0.36 0.40
0.23 0.03 0.08 0.002 0.0004
73 74 74 75 76
FGFR1 SISH 0.25 0.06 0.12 0.05 –0.10 –0.01
0.04 0.64 0.36 0.69 0.39 0.92
68 66 66 69 69 68
The numbers in the first row are the Spearman’s correlation coefficients (r2), in the second row are the p values (p), and the third row are the numbers of observations (n). The sample 
sizes used for the correlation analysis ranged from 66 to 76 due to limits in specimen tumor quality and adequacy for testing of all biomarkers.
FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; mRNA, messenger RNA; IHC, immunohistochemistry; SISH, silver in situ hybridization.
FIGURE 2. A–C, FGFR1, FGF2, and FGF9 mRNA in small-cell lung cancer (in situ hybridization, 200× original magnification). 
Brown dots in cells represent mRNA expression. A, FGFR1 mRNA ISH expression (score = 4); a, FGFR1 mRNA ISH no expression 
(score = 0). B, FGF2 mRNA ISH expression (score = 2). C, FGF9 mRNA ISH expression (score = 2). FGF, fibroblast growth factor; 
FGFR, fibroblast growth factor receptor; mRNA, messenger RNA; ISH, in situ hybridization.
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seven FGFR1 signals and four CEN8 signals per nucleus with 
a normal FGFR1/CEN8 ratio of 1.6. This specimen met our cri-
teria for FGFR1 amplification due to polysomy. The other case 
was not amplified with a mean FGFR1 signal per nucleus of 
2.1 and a FGFR1/CEN8 ratio of 1.1. Neither of those two cases 
had evidence of FGFR1 gene fusions based on the FISH assay.
Correlation Between Protein Expression, 
mRNA Expression, and Gene Amplification 
in the FGF Ligand/Receptor Pathway
We used correlation analysis to compare protein 
expression (FGFR1, FGF2, and FGF9), mRNA expression 
(FGFR1, FGF2, and FGF9), and gene copy number (FGFR1) 
data from the patients with SCLC (Table 1). Analysis of 75 
specimens with complete data for FGFR1 protein, mRNA, 
and gene amplification demonstrated significant correla-
tions between FGFR1 protein and FGFR1 mRNA levels (p < 
0.0001), as well as between FGFR1 protein and FGFR1 gene 
amplification (p = 0.03). Four of the six cases with FGFR1 
amplification (66.7%) were also positive for FGFR1 protein 
expression. FGFR1 mRNA expression levels also correlated 
with FGF2 (p = 0.01) and FGF9 (p = 0.001) protein levels 
(Table 1). Overall, 17 of 75 cases (22.7%) were positive for 
FGFR1 protein expression and/or mRNA expression and/or 
amplification (Table 2).
All but one of the 24 SCLC biopsy samples from the 
German cohort with known FGFR1 amplification could be 
evaluated for FGFR1 protein expression. Seventeen of the 23 
cases (73.9%) were positive for FGFR1 protein expression 
(H-score > 10) and zero in the remaining six cases (26.1%). 
The mean H-score was 68.3. The H-score of positive cases 
ranged from 20 to 210 (Supplementary Table 2, Supplementary 
Digital Content, http://links.lww.com/JTO/A837). Overall, the 
pattern of FGFR1 protein expression appeared homogenous.
Collectively, there were 29 cases with FGFR1 ampli-
fication in the two cohorts. Among these FGFR1 amplified 
cases, 72.4% (21/29) were positive for FGFR1 protein expres-
sion. Of the nonamplified cases within the first cohort, 3% (2 
FIGURE 3. FGFR1 gene amplification in small-
cell lung cancer (silver in situ hybridization, 400× 
original magnification). A, FGFR1 signals are black; 
CEN8 signals are red in nuclei. FGFR1 amplification 
(ratio = 8); a, nonamplified FGFR1 (ratio = 1). FGFR, 
fibroblast growth factor receptor.
TABLE 2.  Characteristics of FGFR1 Positive Cases in the Small-Cell Lung Cancer Tissue Microarray Cohort
Gender Age Amplification Status by SISH mRNA ISH Score H-Score Protein Expression
1 Female 43 Amplified 4 80 Positive
2 Female 51 Amplified 4 285 Positive
3 Male 62 Amplified 4 252 Positive
4 Female 66 Amplified 4 60 Positive
5 Male 64 Not amplifieda 4 56 Positive
6 Male 56 Not amplified 4 40 Positive
7 Male 74 Amplified 0.5 0 Negative
8 Male 59 Amplified No score 0 Negative
9 Male 55 Not amplified 3 0 Negative
10 Male 70 Not amplified 4 0 Negative
11 Female 65 Not amplified 3 0 Negative
12 Male 54 Not amplified 3 0 Negative
13 Male 51 Not amplified 3 0 Negative
14 Female 69 Not amplified 3 0 Negative
15 Male 67 Not amplified 3 0 Negative
16 Male 56 Not amplified 3 0 Negative
17 Female 69 Not amplified 3.5 5 Negative
The positive cases were defined as cases with gene amplification and/or mRNA positivity and/or protein expression positivity.
aCase 5 was negative for FGFR1 gene amplification by SISH but positive by fluorescence in situ hybridization due to polysomy. Tissue was not available from case 8 for testing 
by mRNA ISH.
FGFR, fibroblast growth factor receptor; mRNA, messenger RNA; SISH, silver in situ hybridization; ISH, in situ hybridization; H-score, hybrid scoring system; GCN, gene copy number.
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of 69) were positive for FGFR1 protein expression. Positive 
FGFR1 protein expression was significantly more frequent 
in SCLC amplified cases compared with nonamplified cases 
(Fisher’s exact test, p = 0.0001).
DISCUSSION
The FGF/FGFR signaling axis plays an important 
role in normal organ, vascular, and skeletal development. 
Dysregulation of FGF/FGFR signaling has been observed 
in different tumor settings and plays a key role in driving 
tumor angiogenesis.7 Also, the FGF/FGFR signaling pathway 
has been implicated as an EGFR-therapy resistance pathway 
in studies of lung cancer cell lines, as well as in vivo stud-
ies.6–8,11,12,19 Our studies of protein, mRNA, and gene amplifi-
cation of FGFR1 and its associated ligands, FGF2 and FGF9, 
in resected SCLC specimens provide a better understanding 
of the FGF/FGFR signaling axis biomarkers in SCLC and 
reinforce the FGFR pathway as a potential relevant targeted 
pathway for drug development in SCLC, which has an unmet 
need for new treatment options.
The prevalence of FGFR1 protein expression that we 
detected in the first SCLC cohort (7.2%) was lower than that 
in the study of SCLC by Yang et al.24 (43.7%). This difference 
may be due to a difference in antibodies used (Origene ver-
sus Abcam), specimen processing, scoring protocol, cutoffs 
for positivity, or cohort characteristics. Nevertheless, the high 
level of this discrepancy clearly indicates the need for stan-
dardization. One unknown factor in our study is the role of 
storage on the retrospective analysis of archival material. The 
stability of the FGFR1 protein over time is not known. As with 
all biomarkers, it will be important to develop standardized 
methods for IHC evaluation of FGFR1 protein expression. 
Analysis comparing FGFR1 protein expression with stage 
was inconclusive due to the small number of positive samples 
(n = 6). The prior study by Yang et al.24 suggests that FGFR1 
protein expression in SCLC may be associated with stage.
The prevalence of FGFR1 mRNA positive expression in 
this current SCLC study (19.7%) is lower than that in our prior 
studies in SqCC (28%, n = 89) and adenocarcinoma (22%, 
n = 45).11 The prevalence of FGFR1 amplification in our SCLC 
cohort by SISH (7.8%) is similar to that in prior SCLC stud-
ies of FGFR1 amplification by FISH (5.6–7% prevalence).18,25 
The FGFR1 amplification prevalence in SCLC specimens is 
lower than that reported for SqCC specimens (13–25%).8–10 
Interestingly, FGFR1 amplification by FISH was not observed 
in a study including 97 lung adenocarcinomas (0%).26 These 
differences in FGFR1 amplification prevalence may be attrib-
uted to several factors, including a different prevalence of 
smoking associated with these tumor subtypes.27 Indeed, 
almost all of patients with SCLC and SqCC are smokers.28
FGFR1 protein expression significantly correlated with 
both FGFR1 mRNA expression level (p < 0.0001) and FGFR1 
gene copy number (p = 0.03). Of note, all cases with posi-
tive protein expression had the highest score (score of 4) for 
FGFR1 mRNA expression. Five of six specimens positive for 
protein expression were also positive for FGFR1 amplifica-
tion by SISH or FISH. FISH detected amplification due to 
polysomy in one specimen that was negative for amplification 
by SISH. Possible explanations for this discrepancy between 
the SISH and FISH are tumor heterogeneity, differences in 
specimen processing, assay sensitivities, or scoring criteria.
FGFR1 gene copy number has been used as a biomarker 
in multiple studies to predict sensitivity to FGFR1 inhibi-
tors,8,9,29 but a recent preclinical study concludes that FGFR1 
protein and mRNA expression predict tyrosine kinase inhibi-
tor sensitivity better than FGFR1 gene copy number.11 In addi-
tion, some phase I studies using FGFR inhibitors in patients 
with advanced solid tumors suggest that FGFR1 amplifica-
tion is not an absolute predictor of FGFR inhibition.8,30,31 
Furthermore, fusions of the FGFR gene have been described 
in NSCLC, but their clinical significance is still unknown.32,33 
We are not aware of any fusions/mutations described in SCLC. 
In comparing methodologies for screening, it is important 
to consider the lower cost and greater availability of IHC in 
pathology laboratories compared with methods such as FISH, 
which requires more specialized training and equipment.
Similar to studies of other biomarkers, such as ALK and 
EGFR, we identified several cases with discrepancies between 
positivity for FGFR1 protein expression, mRNA expression, 
and gene copy number. Other preclinical FGFR1 studies have 
also reported on such discrepancies.11,34,35 FISH methodol-
ogy may not detect complex amplifications or other altera-
tions of the FGFR1 gene, such as point mutations, fusions, 
and chromosomal translocations, which may all result in 
changes in protein expression. However, several patients with 
NSCLC and positive ALK protein expression but negative 
ALK amplification have shown dramatic response to ALK 
inhibitors.35–37 In a recent study, FISH and IHC were system-
atically used to test for EML4-ALK rearrangements in 51 lung 
adenocarcinoma specimens, with additional testing of discor-
dant cases by next-generation sequencing.38 Next-generation 
sequencing confirmed ALK alterations in four of five patients 
who were positive with IHC and negative with FISH. Two 
of these IHC-positive, FISH-negative patients were treated 
with crizotinib and had progression-free survival of 6 and 18 
months.38 Thus, patients with changes in a biomarker protein 
or mRNA expression may benefit from directed therapy, even 
without a detected genetic abnormality for the correspond-
ing biomarker gene.11 Hence, we suggest that patients with 
SCLC with positive FGFR1, FGF2, and FGF9 protein and/
or mRNA expression levels be considered for further clinical 
studies of FGFR inhibitors.
Our analysis showed that FGFR1 mRNA expression 
correlated with both FGF2 and FGF9 mRNA levels, as well as 
with FGF2 and FGF9 protein levels. These findings are con-
sistent with several independent studies, which have shown 
coexpression of FGF2 and FGFR1 in NSCLC specimens.5,39 
Some researchers propose that coexpression of FGFR1 and 
one or more ligands represent the oncogenic driving event in 
lung cancer.11 FGFR1 and ligand double positivity may more 
accurately represent SCLC driven by the FGF signaling path-
way than FGFR1, FGF2, or FGF9 as single biomarkers.11
In summary, a subset of patients with SCLC is char-
acterized by tumors with potentially activated FGF/FGFR1 
pathways, as evidenced by positive FGF2, FGF9, and FGFR1 
protein and/or mRNA expression and/or FGFR1 gene copy 
number. Further studies are needed to determine whether or 
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not this subset of SCLC patients would benefit from FGF/
FGFR1-directed targeted therapies.
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